Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

RADIOTHERAPY

Use of genomics to balance cure and complications

The identification of biomarkers and the development of genomics-based assays predictive of outcomes following radiotherapy, in an effort to help guide the treatment of patients with cancer, is an area of increasing research interest. Here, we discuss the validity of one such classifier, ARTIC, in the context of complementary genomic approaches designed to predict both tumour response and the susceptibility of nonmalignant tissues to toxicities resulting from radiotherapy.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    van Leeuwen, C. M. et al. The alfa and beta of tumours: a review of parameters of the linear-quadratic model, derived from clinical radiotherapy studies. Radiat. Oncol. 13, 96 (2018).

    Article  Google Scholar 

  2. 2.

    Yard, B. D. et al. A genetic basis for the variation in the vulnerability of cancer to DNA damage. Nat. Commun. 7, 11428 (2016).

    CAS  Article  Google Scholar 

  3. 3.

    Azria, D. et al. Data-based radiation oncology: design of clinical trials in the toxicity biomarkers era. Front. Oncol. 7, 83 (2017).

    Article  Google Scholar 

  4. 4.

    Sjostrom, M. et al. Clinicogenomic radiotherapy classifier predicting the need for intensified locoregional treatment after breast-conserving surgery for early-stage breast cancer. J. Clin. Oncol. https://doi.org/10.1200/JCO.19.00761 (2019).

    Article  Google Scholar 

  5. 5.

    Ahmed, K. A. et al. Utilizing the genomically adjusted radiation dose (GARD) to personalize adjuvant radiotherapy in triple negative breast cancer management. EBioMedicine 47, 163–169 (2019).

    Article  Google Scholar 

  6. 6.

    Rosenstein, B. S. Radiogenomics: identification of genomic predictors for radiation toxicity. Semin. Radiat. Oncol. 27, 300–330 (2017).

    Article  Google Scholar 

  7. 7.

    Azria, D. et al. Radiation-induced CD8 T-lymphocyte apoptosis as a predictor of breast fibrosis after radiotherapy: results of the prospective multicenter french trial. EBioMedicine 2, 1965–1973 (2015).

    Article  Google Scholar 

  8. 8.

    West, C. et al. The REQUITE project: validating predictive models and biomarkers of radiotherapy toxicity to reduce side-effects and improve quality of life in cancer survivors. Clin. Oncol. (R. Coll. Radiol.) 26, 739–742 (2014).

    CAS  Article  Google Scholar 

  9. 9.

    Kerns, S. L. et al. Radiogenomics consortium genome-wide association study meta-analysis of late toxicity after prostate cancer radiotherapy. J. Natl. Cancer Inst. https://doi.org/10.1093/jnci/djz075 (2019).

    Article  PubMed  Google Scholar 

  10. 10.

    Kang, J. et al. Machine learning and radiogenomics: lessons learned and future directions. Front. Oncol. 8, 228 (2018).

    Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Barry S. Rosenstein.

Ethics declarations

Competing interests

David Azria is a founder of NovaGray. B.R. declares no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Azria, D., Rosenstein, B.S. Use of genomics to balance cure and complications. Nat Rev Clin Oncol 17, 9–10 (2020). https://doi.org/10.1038/s41571-019-0306-1

Download citation

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing